No abstract

The strength distributions of the giant monopole resonance (GMR) have been measured in the even-A Sn isotopes (A=112-124) with inelastic scattering of 400-MeV alpha particles in the angular range 0 degrees -8.5 degrees . We find that the experimentally observed GMR energies of the Sn isotopes are lower than the values predicted by theoretical calculations that reproduce the GMR energies in 208Pb and 90Zr very well. From the GMR data, a value of Ktau = -550 +/- 100 MeV is obtained for the asymmetry term in the nuclear incompressibility.

We have investigated the isoscalar giant resonances in the Sn isotopes using inelastic scattering of 386-MeV α-particles at extremely forward angles, including 0 • . We have obtained completely "background-free" inelastic-scattering spectra for the Sn isotopes over the angular range 0 • -9 • and up to an excitation energy of 31.5 MeV. The strength distributions for various multipoles were extracted by a multipole decomposition analysis based on the expected angular distributions of the respective multipoles. We find that the centroid energies of the isoscalar giant monopole resonance (ISGMR) in the Sn isotopes are significantly lower than the theoretical predictions. In addition, based on the ISGMR results, a value of K τ = −550 ± 100 MeV is obtained for the asymmetry term in the nuclear incompressibility. Constraints on interactions employed in nuclear structure calculations are discussed on the basis of the experimentally-obtained values for K ∞ and K τ .2

Peritoneal dissemination is a common cause of death from gastrointestinal cancers and is difficult to treat using current therapeutic options, particularly late-phase disease. Here, we investigated the feasibility of integrated therapy using 64Cu-intraperitoneal radioimmunotherapy (ipRIT), alone or in combination with positron emission tomography (PET)-guided surgery using a theranostic agent (64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab) to treat early- and late-phase peritoneal dissemination in mouse models. In this study, we utilized the OpenPET system, which has open space for conducting surgery while monitoring objects at high resolution in real time, as a novel approach to make PET-guided surgery feasible. 64Cu-ipRIT with cetuximab inhibited tumor growth and prolonged survival with little toxicity in mice with early-phase peritoneal dissemination of small lesions. For late-phase peritoneal dissemination, a combination of 64Cu-ipRIT for down-staging and subsequent OpenPET-guided surgery for resecting large tumor masses effectively prolonged survival. OpenPET clearly detected tumors (≥3 mm in size) behind other organs in the peritoneal cavity and was useful for confirming the presence or absence of residual tumors during an operation. These findings suggest that integrated 64Cu therapy can serve as a novel treatment strategy for peritoneal dissemination.

No abstract